Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average rating of “Buy” from the twenty-two ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nineteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $117.00.

Several equities research analysts have issued reports on KYMR shares. Jefferies Financial Group boosted their price objective on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. HC Wainwright upped their price target on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Stephens raised their price objective on Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Royal Bank Of Canada boosted their price objective on Kymera Therapeutics from $70.00 to $103.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Finally, Wells Fargo & Company increased their target price on Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $79.59 on Monday. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00. The firm has a market capitalization of $5.73 billion, a P/E ratio of -22.17 and a beta of 2.21. The business’s 50-day simple moving average is $76.61 and its 200-day simple moving average is $61.03.

Insider Transactions at Kymera Therapeutics

In other news, insider Jared Gollob sold 49,307 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the transaction, the insider directly owned 109,992 shares in the company, valued at approximately $9,752,990.64. This represents a 30.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total transaction of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 420,895 shares of company stock worth $37,778,351 over the last 90 days. 16.01% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Large investors have recently modified their holdings of the business. Farther Finance Advisors LLC lifted its stake in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after acquiring an additional 540 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.